786 results on '"Wesseling, Pieter"'
Search Results
2. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting
3. Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors
4. Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
5. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups
6. Sex-related incidence and survival differences in pediatric high-grade glioma subtypes: A population-based cohort study
7. Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
8. Oligosarcomas, IDH-mutant are distinct and aggressive
9. Fast intraoperative histology-based diagnosis of gliomas with third harmonic generation microscopy and deep learning
10. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather
11. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
12. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum
13. Counting mitoses: SI(ze) matters!
14. Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin
15. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
16. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1
17. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
18. Identification of a putative molecular subtype of adult-type diffuse astrocytoma with recurrent MAPK pathway alterations.
19. AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper.
20. Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma
21. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis
22. Sarcoma classification by DNA methylation profiling
23. Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting
24. Postoperative oscillatory brain activity as an add-on prognostic marker in diffuse glioma
25. p120-catenin-dependent collective brain infiltration by glioma cell networks
26. Longitudinal molecular trajectories of diffuse glioma in adults
27. The molecular landscape of ETMR at diagnosis and relapse
28. RT-PCR assay to detect FGFR3::TACC3 fusions in formalin-fixed, paraffin-embedded glioblastoma samples.
29. The immunological landscape of peripheral blood in glioblastoma patients and immunological consequences of age and dexamethasone treatment.
30. WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?
31. Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1
32. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma
33. Prognostic significance of NAB2–STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear
34. Oscillatory brain activity associates with neuroligin-3 expression and predicts progression free survival in patients with diffuse glioma
35. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
36. Impact of MR-guided boiling histotripsy in distinct murine tumor models
37. Quantitative parametric maps of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma
38. Deep learning-based group-wise registration for longitudinal MRI analysis in glioma
39. Reconstructing the molecular life history of gliomas
40. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant
41. DNA methylation-based classification of central nervous system tumours
42. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)
43. Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification (Acta Neuropathologica, (2023), 145, 1, (49-69), 10.1007/s00401-022-02516-2)
44. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline.
45. PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.
46. Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment
47. Glioma: experimental models and reality
48. Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle
49. Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?
50. Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.